Recurrent Glioblastoma Multiforme Treatment Market Share Is Estimated to Grow at a CAGR of 6.14% By 2027 | Future Growth Analysis, Emerging Trends and Global Industry Insights
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Recurrent Glioblastoma Multiforme Treatment Market, by Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 369.6 million in 2020 and is expected to exhibit a CAGR of 6.14% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
For more Information, Request PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/682
Key players are involved in strategic collaborations to expand their market presence. For instance, in May 2017, DelMar Pharmaceuticals entered into a collaboration agreement with PRA Health Sciences, a contract research organization (CRO), to conduct phase III trials of VAL-083 for the treatment of recurrent glioblastoma multiforme. A global leader of CRO, PRA Health Sciences, provides outsourced clinical development services to the biotechnology as well as pharmaceutical industries.
For instance, in January 2020, a bevacizumab biosimilar, Zirabev, was launched by Pfizer in the U.S. for the treatment of recurrent GBM. Zirabev represents Avastin, which is priced at US$ 61.34 per 10 mg at Wholesale Acquisition Cost (WAC). FDA approved the biosimilar in June 2019 for the treatment of recurrent or metastatic NSCLC, metastatic cell carcinoma, metastatic colorectal cancer, recurrent glioblastoma multiforme, and persistent/recurrent or metastatic cervical cancer.
Recurrent Glioblastoma Multiforme Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 outbreak has immensely affected the recurrent glioblastoma multiforme treatment market growth. According to the Centers for Disease Control and Prevention (CDC), patients aged 65 years & above and those with hysterical comorbidities are considered at high risk of being affected with COVID-19 infection. Therefore, based on these risk factors, it is recommended to the glioblastoma multiforme patients with recurrent GBM to be strongly considered for hypofractionated RT regimens. The recurrent GBM industry is likely to get impacted due to COVID-19 pandemic and the treatments for this disease will evolve in the near future.
Browse 26 Market Data Tables and 28 Figures spread through 160 Pages and in-depth TOC on Recurrent Glioblastoma Multiforme Treatment Market, By Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027”
To know the latest trends and insights related to recurrent glioblastoma multiforme treatment market press release, click the link below: https://www.coherentmarketinsights.com/press-release/recurrent-glioblastoma-multiforme-treatment-market-3381
Key players in the market are adopting several strategies such as mergers & acquisitions, collaborations, and joint ventures to strengthen their position in the global market. For instance, in October 2019, Advaxix and UCLA entered into a research agreement for the development of GBM immunotherapy products. The company aims to conduct preclinical studies assessing the Lm technology of UCLA in mouse tumor models of glioblastoma multiforme.
Key Takeaways of the Global Recurrent Glioblastoma Multiforme Treatment Market:
- The global recurrent glioblastoma multiforme treatment market is expected to exhibit a CAGR of 6.14% during the forecast period (2020-2027), owing to rising prevalence of seizures and the advancements in treatment & partnerships among market players
- Among type, the grade IV segment accounted for significant revenue share, owing to increasing prevalence of such conditions. For instance, according to the American Association of Neurological Surgeons (AANS), the prevalence of GBM accounts for around 52% of all the primary brain tumors.
- Major players operating in the global recurrent glioblastoma multiforme treatment market include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/682
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By Type
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Technological Advancements in Recurrent Glioblastoma Multiforme Treatment
- Key Developments
- Acquisition, Collaborations & Partnerships
- Epidemiology
- Reimbursement Analysis
- Pipeline Analysis
- Pricing Analysis
- Treatment Algorithm
- Market Dynamics
- Global Recurrent Glioblastoma Multiforme Treatment Market, Impact of Coronavirus (Covid-19) Pandemic
- Pre-COVID Situation
- Post-COVID Demand
- Need for Recurrent Glioblastoma Multiforme Treatment
- Recommendations and Guidelines by Regulatory Bodies
- Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Radiosensitizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Nitrosoureas Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Recurrent Glioblastoma Multiforme Treatment Market, By Type, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Grade II or Grade III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Grade IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Recurrent Glioblastoma Multiforme Treatment Market, By Region, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027(%)
- Y-o-Y Growth Analysis, By Region, 2017 –2027
- Regional Trends
- North America
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Company Profiles
- GlaxoSmithKline, Plc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Astrazeneca
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hoffman-La Roche, Ltd.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Merck & Co., Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Vascular Biogeneics
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AngioChem, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boston Biomedical, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cantex Pharmaceuticals, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Celldex Therapeutics, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cavion LLC
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Coherus BioSciences, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eisai
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eli Lilly and Company
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cortice Biosciences, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- EnGeneIC Ltd.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GenSpera, Inc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ERC Belgium SA
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Genzyme Corporation
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ImmunoCellular Therapeutics, Ltd.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GW Pharmaceuticals Plc.
- Company Overview
- Treatment Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline, Plc.
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
